Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

Medically reviewed by Casey Gallagher, MD Psoriasis of the hands and feet, known as palmoplantar psoriasis, is an inflammatory autoimmune disorder that causes scaly, itchy skin patches on the palms ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...

"This is the first time I'm really talking about it publicly… but you just get that 'aha' moment where you realize 'I wasn't put in this position to not utilize my voice and my platform for good." La ...

Top line results for the Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies 2 in moderate to severe plaque psoriasis, are expected in Q4 2024. Top line results for the Phase 2b ANTHEM multicenter, ...

which is heading for an FDA decision next September in moderate to severe plaque psoriasis. That's important because deucravacitinib – aiming to become the first tyrosine kinase 2 (TYK2 ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments," said Samit ...

This also differentiates it from plaque psoriasis, which often affects extensor surfaces ... is used with caution as it can sometimes trigger a flare or, worse yet, a severe form of the disease known ...